S125: 10-DAY DECITABINE VS. CONVENTIONAL CHEMOTHERAPY ("3 + 7") FOLLOWED BY ALLOGRAFTING (HSCT) IN AML PATIENTS ≥60 YEARS: A RANDOMIZED PHASE III STUDY OF THE EORTC LEUKEMIA GROUP, GIMEMA, CELG, AND GMDS-SG. (23rd June 2022)

• Record Type: Journal Article
• Authors: Lübbert, M.; Wijermans, P.; Kicinski, M.; Chantepie, S.; van der Velden, W.; Noppeney, R.; Griskevicius, L.; Neubauer, A.; Crysandt, M.; Vrhovac, R.; Luppi, M.; Fuhrmann, S.; Audisio, E.; Candoni, A.; Legrand, O.; Foà, R.; Gaidano, G.; van Lammeren-Venema, D.; Posthuma, E. F.; Hoogendoorn, M.; Giraut, A.; Stevens-Kroef, M.; Jansen, J. H.; Ammatuna, E.; Vilque, J.-P.; Wäsch, R.; Becker, H.; Blijlevens, N.; Dührsen, U.; Baron, F.; Suciu, S.; Amadori, S.; Venditti, A.; Huls, G.;
• Is Part Of: HemaSphere. Volume 6(2022)Supplement 3
• Page Start: 26
• Page End: 27
• Publication Date: 2022-06-23
• Subjects: Hematology -- Periodicals; 616.15005
• DOI: 10.1097/01.HS9.0000843392.61672.18
• Languages: English
• ISSNs: 2572-9241